Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study
- PMID: 29536241
- DOI: 10.1007/s00330-017-5166-4
Combined transcatheter arterial chemoembolization and radiofrequency ablation versus hepatectomy for recurrent hepatocellular carcinoma after initial surgery: a propensity score matching study
Abstract
Objectives: To compare retrospectively the efficacy of transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) (TACE-RFA) with that of repeat hepatectomy in the treatment of initial recurrent hepatocellular carcinoma (HCC) after hepatectomy by propensity score matching (PSM).
Methods: From September 2006 to June 2015, 186 patients who underwent TACE-RFA (n=107) or repeat hepatectomy (n=79) for recurrent HCC ≤ 5.0 cm were included. The overall survival (OS) and disease-free survival (DFS) were compared. PSM was used to correct potential confounding factors between these two groups.
Results: 1-, 3-, and 5-year OS rates after TACE-RFA and repeat hepatectomy were 84.6%, 66.9%, 49.1%, and 84.8%, 60.2%, 51.9%, respectively (p=.871). The corresponding DFS rates were 58.2%, 35.2%, 29.6% and 64.8%, 41.6%, 38.3% (p=.258). TACE-RFA has lower major complication rates (p=.009) and shorter hospital stay (p<.001). After PSM, 1-, 3-, 5- year OS rates after TACE-RFA (n=51) and repeat hepatectomy (n=51) were 84.3%, 60.4%, 46.4% and 84.3%, 64.5%, 49.8% (p=.951), the corresponding DFS rates were 54.9%, 35.0%, 30.6% and 58.7%, 35.8%, and 33.6% (p=.733). AFP and micro-vessel invasion of initial tumour were significant prognostic factors for OS and DFS, respectively.
Conclusions: TACE-RFA provides comparable OS and DFS to repeat hepatectomy, fewer major complications and shorter hospital stay.
Key points: • TACE-RFA achieved similar OS and DFS with repeat hepatectomy for recurrent HCC • Major complication rate was lower in the TACE-RFA group • The hospital stay was shorter in the TACE-RFA group • AFP was a predictor for OS, MVI was a predictor for DFS • The treatment strategies were not significant prognostic factor for OS or DFS.
Keywords: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Propensity Score; Radio waves.
Similar articles
-
Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.J Cancer Res Clin Oncol. 2020 Oct;146(10):2669-2680. doi: 10.1007/s00432-020-03254-2. Epub 2020 May 25. J Cancer Res Clin Oncol. 2020. PMID: 32449005 Free PMC article.
-
The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC.Eur Radiol. 2020 Jun;30(6):3473-3485. doi: 10.1007/s00330-019-06640-8. Epub 2020 Feb 11. Eur Radiol. 2020. PMID: 32048035
-
Comparison of combined transcatheter arterial chemoembolization and radiofrequency ablation with surgical resection by using propensity score matching in patients with hepatocellular carcinoma within Milan criteria.Radiology. 2013 Dec;269(3):927-37. doi: 10.1148/radiol.13130387. Epub 2013 Oct 28. Radiology. 2013. PMID: 24086071
-
Trans-arterial chemoembolization + radiofrequency ablation versus surgical resection in hepatocellular carcinoma - A meta-analysis.Eur J Surg Oncol. 2020 May;46(5):763-771. doi: 10.1016/j.ejso.2020.01.004. Epub 2020 Jan 7. Eur J Surg Oncol. 2020. PMID: 31937433 Review.
-
The clinical efficiency of TACE combined with simultaneous computed tomography-guided radiofrequency ablation for advanced hepatocellular carcinoma.Invest New Drugs. 2021 Oct;39(5):1383-1388. doi: 10.1007/s10637-021-01101-w. Epub 2021 Mar 22. Invest New Drugs. 2021. PMID: 33754235 Review.
Cited by
-
Transarterial Chemoembolization Combined with Microwave Ablation in Elderly Patients with Recurrent Medium or Large Hepatocellular Carcinoma.J Hepatocell Carcinoma. 2024 Oct 22;11:2005-2017. doi: 10.2147/JHC.S455411. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39465044 Free PMC article.
-
Current status and prospect of treatments for recurrent hepatocellular carcinoma.World J Hepatol. 2023 Feb 27;15(2):129-150. doi: 10.4254/wjh.v15.i2.129. World J Hepatol. 2023. PMID: 36926237 Free PMC article. Review.
-
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib.Cancers (Basel). 2018 Dec 14;10(12):516. doi: 10.3390/cancers10120516. Cancers (Basel). 2018. PMID: 30558224 Free PMC article.
-
Repeat hepatectomy versus thermal ablation therapy for recurrent hepatocellular carcinoma: a systematic review and meta-analysis.Front Oncol. 2024 Mar 28;14:1370390. doi: 10.3389/fonc.2024.1370390. eCollection 2024. Front Oncol. 2024. PMID: 38606103 Free PMC article. Review.
-
Threatment Strategies for Recurrent Hepatocellular Carcinoma Patients: Ablation and its Combination Patterns.J Cancer. 2024 Feb 25;15(8):2193-2205. doi: 10.7150/jca.93885. eCollection 2024. J Cancer. 2024. PMID: 38495485 Free PMC article. Review.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous